These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 9751088

  • 21. Minimal disease activity for rheumatoid arthritis: a preliminary definition.
    Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landewé RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Van der Heijde DM, van Riel PL, Wolfe F, Tugwell PS.
    J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 23. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R.
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [Abstract] [Full Text] [Related]

  • 24. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P, Levine M, Gaebel K, Thabane L.
    Can J Clin Pharmacol; 2005 Apr; 12(3):e254-63. PubMed ID: 16278497
    [Abstract] [Full Text] [Related]

  • 25. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [Abstract] [Full Text] [Related]

  • 31. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ.
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 33. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis.
    McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, Bustillo J, Gonzalez M, Kaeley G, Steere EL, Somes GW, Myers LK, Seyer JM, Kang AH, Postlethwaite AE.
    Arthritis Rheum; 1999 Jun; 42(6):1204-8. PubMed ID: 10366113
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.
    Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B.
    J Rheumatol; 2006 Feb 05; 33(2):234-43. PubMed ID: 16465653
    [Abstract] [Full Text] [Related]

  • 36. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
    Mäkinen H, Kautiainen H, Hannonen P, Sokka T.
    J Rheumatol; 2008 Aug 05; 35(8):1522-7. PubMed ID: 18484699
    [Abstract] [Full Text] [Related]

  • 37. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 05; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 38. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis.
    Choi HK, Seeger JD, Kuntz KM.
    Arthritis Rheum; 2000 Oct 05; 43(10):2316-27. PubMed ID: 11037892
    [Abstract] [Full Text] [Related]

  • 39. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan 05; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 40. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
    Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M, 990136 Study Group.
    J Rheumatol; 2005 Dec 05; 32(12):2303-10. PubMed ID: 16331754
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.